In this study, we first verify the role of hENT1 as a prognostic predictor for pancreatic cancer patients who underwent radical surgery followed by intra-arterial infusion of gemcitabine-based chemotherapy, in order to select beneficiaries of this chemo-therapeutic strategy. The gene discussed is SLC29A1; the disease is pancreatic neoplasm.